Wistar researchers in the Vaccine & Immunotherapy Center continue their concerted efforts to develop additional preventative and drug discovery approaches that could complement the existing vaccines and will add more tools to our preparedness resources, and to unravel the viral mechanisms of disease. The technologies under development are also being tested against some of the new viral variants.
Wistar continues to follow the Centers for Disease Control and Prevention guidelines.
A new COVID-19 vaccine developed by Wistar scientists uses immune focusing and self-assembling nanoparticles to elicit higher levels of neutralizing antibodies. Animal studies show it offers stronger, broader and more durable protection from a single, lower dose — including protection from variants.